Shanghai Bio-heart Biological Technology Co., Ltd. operates as an interventional cardiovascular device company in the People's Republic of China. The company focuses on the provision of bioresorbable scaffolds (BRS) and renal denervation (RDN) therapies for the treatment of coronary artery diseases and uncontrolled and resistant hypertension. It is developing Bioheart, a BRS system used in percutaneous coronary intervention procedures for the treatment of coronary artery disease; Iberis 2nd, a multi-electrode RDN product candidate; and drug coated balloon, a sirolimus drug-eluting balloon catheter designed for instent restenosis. The company has collaboration agreements with Terumo (China) Investment Co., Ltd. to conduct clinical trials for Iberis 2nd. Shanghai Bio-heart Biological Technology Co., Ltd. was founded in 2014 and is headquartered in Shanghai, the People's Republic of China.
Shanghai Bio-heart Biological Technology Dividend Announcement
• Shanghai Bio-heart Biological Technology does not currently offer dividends, we're keeping a close eye on its growth potential and financial developments.
• Stay tuned for updates on Shanghai Bio-heart Biological Technology dividend policy and future announcements. In the meantime, explore other dividend-yielding opportunities on our website.
Shanghai Bio-heart Biological Technology Dividend History
Shanghai Bio-heart Biological Technology Dividend Yield
Shanghai Bio-heart Biological Technology current trailing twelve-month (TTM) dividend yield is -%. Interested in purchasing Shanghai Bio-heart Biological Technology stock? Use our calculator to estimate your expected dividend yield:
Shanghai Bio-heart Biological Technology Financial Ratios
Shanghai Bio-heart Biological Technology Dividend FAQ
1. Growth opportunities: Companies, especially in fast-growing industries like technology, reinvest earnings into expansion, R&D, or acquisitions to fuel future growth and increase company value.
2. Tax implications: Not paying dividends can reduce the tax burden on shareholders, who may prefer to defer taxes until selling shares and realizing capital gains.
3. Investor preferences: Some investors prefer companies to reinvest profits for higher long-term returns, particularly those seeking capital appreciation over income.
4. Capital allocation priorities: Companies may allocate cash to pay down debt, fund share buybacks, or invest in projects with higher returns than dividends.
5. Market expectations: In certain sectors, like technology, reinvesting profits for growth and innovation is often prioritized over distributing dividends to shareholders.
Place an order: Use the brokerage's trading platform to place an order to buy Shanghai Bio-heart Biological Technology stock.
Remember that buying stocks involves risk, and it's important to carefully consider your investment goals, risk tolerance, and conduct thorough research before making any investment decisions.